AbbVie Acquires Capstan Therapeutics in $2.1 Billion Deal to Expand Immunotherapy Portfolio

Ropes & Gray has advised AbbVie on the transaction, and Cooley has advised Capstan TherapeuticsAbbVie has announced the acquisition of Capstan Therapeutics in a transaction valued…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Leila Ahmed

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here